These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 24999589)

  • 1. Promoter CpG island hypermethylation in dysplastic nevus and melanoma: CLDN11 as an epigenetic biomarker for malignancy.
    Gao L; van den Hurk K; Moerkerk PTM; Goeman JJ; Beck S; Gruis NA; van den Oord JJ; Winnepenninckx VJ; van Engeland M; van Doorn R
    J Invest Dermatol; 2014 Dec; 134(12):2957-2966. PubMed ID: 24999589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a Robust Methylation Classifier for Cutaneous Melanoma Diagnosis.
    Conway K; Edmiston SN; Parker JS; Kuan PF; Tsai YH; Groben PA; Zedek DC; Scott GA; Parrish EA; Hao H; Pearlstein MV; Frank JS; Carson CC; Wilkerson MD; Zhao X; Slater NA; Moschos SJ; Ollila DW; Thomas NE
    J Invest Dermatol; 2019 Jun; 139(6):1349-1361. PubMed ID: 30529013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genome-wide promoter methylation analysis identifies epigenetic silencing of MAPK13 in primary cutaneous melanoma.
    Gao L; Smit MA; van den Oord JJ; Goeman JJ; Verdegaal EM; van der Burg SH; Stas M; Beck S; Gruis NA; Tensen CP; Willemze R; Peeper DS; van Doorn R
    Pigment Cell Melanoma Res; 2013 Jul; 26(4):542-54. PubMed ID: 23590314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA-methylation profiling distinguishes malignant melanomas from benign nevi.
    Conway K; Edmiston SN; Khondker ZS; Groben PA; Zhou X; Chu H; Kuan PF; Hao H; Carson C; Berwick M; Olilla DW; Thomas NE
    Pigment Cell Melanoma Res; 2011 Apr; 24(2):352-60. PubMed ID: 21375697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RASSF10 promoter hypermethylation is frequent in malignant melanoma of the skin but uncommon in nevus cell nevi.
    Helmbold P; Richter AM; Walesch S; Skorokhod A; Marsch WCh; Enk A; Dammann RH
    J Invest Dermatol; 2012 Mar; 132(3 Pt 1):687-94. PubMed ID: 22113481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic Characterization of Dysplastic Nevi Unveils Implications for Diagnosis of Melanoma.
    Melamed RD; Aydin IT; Rajan GS; Phelps R; Silvers DN; Emmett KJ; Brunner G; Rabadan R; Celebi JT
    J Invest Dermatol; 2017 Apr; 137(4):905-909. PubMed ID: 27890785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Promoter methylation as biomarkers for diagnosis of melanoma: A systematic review and meta-analysis.
    Guo Y; Long J; Lei S
    J Cell Physiol; 2019 May; 234(5):7356-7367. PubMed ID: 30370527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dysplastic Nevi: Morphology and Molecular and the Controversies In-between.
    Wiedemeyer K; Hartschuh W; Brenn T
    Surg Pathol Clin; 2021 Jun; 14(2):341-357. PubMed ID: 34023110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of DNA ploidy in dysplastic and Spitz nevi by flow cytometry.
    Winokur TS; Palazzo JP; Johnson WC; Duray PH
    J Cutan Pathol; 1990 Dec; 17(6):342-7. PubMed ID: 2074280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dysplastic melanocytic nevi and cutaneous melanoma: markers of increased melanoma risk for affected persons and blood relatives.
    Albert LS; Rhodes AR; Sober AJ
    J Am Acad Dermatol; 1990 Jan; 22(1):69-75. PubMed ID: 2298967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dysplastic nevus part II: Dysplastic nevi: Molecular/genetic profiles and management.
    Spaccarelli N; Drozdowski R; Peters MS; Grant-Kels JM
    J Am Acad Dermatol; 2023 Jan; 88(1):13-20. PubMed ID: 36252690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CpG island methylator phenotype predicts progression of malignant melanoma.
    Tanemura A; Terando AM; Sim MS; van Hoesel AQ; de Maat MF; Morton DL; Hoon DS
    Clin Cancer Res; 2009 Mar; 15(5):1801-7. PubMed ID: 19223509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TSLC1 expression discriminates cutaneous melanomas from dysplastic nevi.
    You Y; Wang SH; Zhang JF; Zheng SY
    Melanoma Res; 2012 Dec; 22(6):430-5. PubMed ID: 23047161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclin D1 and D3 expression in melanocytic skin lesions.
    Alekseenko A; Wojas-Pelc A; Lis GJ; Furgał-Borzych A; Surówka G; Litwin JA
    Arch Dermatol Res; 2010 Sep; 302(7):545-50. PubMed ID: 20496072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Claudin11 Promoter Hypermethylation Is Frequent in Malignant Melanoma of the Skin, but Uncommon in Nevus Cell Nevi.
    Walesch SK; Richter AM; Helmbold P; Dammann RH
    Cancers (Basel); 2015 Jul; 7(3):1233-43. PubMed ID: 26198249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dermatoscopy of "dysplastic nevi": a beacon in diagnostic darkness.
    Roesch A; Burgdorf W; Stolz W; Landthaler M; Vogt T
    Eur J Dermatol; 2006; 16(5):479-93. PubMed ID: 17101467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PRAME expression in melanocytic proliferations with intermediate histopathologic or spitzoid features.
    Raghavan SS; Wang JY; Kwok S; Rieger KE; Novoa RA; Brown RA
    J Cutan Pathol; 2020 Dec; 47(12):1123-1131. PubMed ID: 32700786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA ploidy and nuclear morphometry for the classification of dysplastic nevi.
    Williams RA; Baak JP; Meijer GA; Charlton IG
    Anal Quant Cytol Histol; 1999 Oct; 21(5):437-44. PubMed ID: 10560527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A natural history of melanomas and dysplastic nevi: an atlas of lesions in melanoma-prone families.
    Tucker MA; Fraser MC; Goldstein AM; Struewing JP; King MA; Crawford JT; Chiazze EA; Zametkin DP; Fontaine LS; Clark WH
    Cancer; 2002 Jun; 94(12):3192-209. PubMed ID: 12115352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dysplastic nevi.
    Farber MJ; Heilman ER; Friedman RJ
    Dermatol Clin; 2012 Jul; 30(3):389-404. PubMed ID: 22800547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.